Icure Pharmaceutical Incorporation

175250KOSDAQChemicals and chemical products

Icure Pharmaceutical Incorporation (175250, KOSDAQ) reported KRW 83bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202164-28-3821599Consolidated
202259-27-4322492Consolidated
202357-23-3216660Consolidated
202469-17013361Consolidated
202583-12-359024Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2021-44%-59.7%45.8%-38.9%
2022-45.1%-71.7%41%-46.3%
2023-39.9%-56.9%35.9%-54.2%
2024-24.8%0%45.7%0%
2025-14.3%-41.4%27%-141.1%

Revenue moved 29.7% between 2021 and 2025.

Net profit was negative in the 1 most recent year on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 67bn
Close priceKRW 1,791
Listed shares37,558,368
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Lee Yeong-seok (이영석)Representative Director (CEO)Inside director5 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)286
Women160 (55.9%)
Average tenure2.7 years
Annual pay, menKRW 12,188,921
Annual pay, womenKRW 9,551,031
Pay ratio, women to men78.4%

Other companies in Chemicals and chemical products

173 listed companies file under this classification. Showing 12.

See the whole Chemicals and chemical products list →